(RTTNews) - uniQure N.V. (QURE) announced that the company received final meeting minutes from the FDA regarding a pre-Biologics License Application meeting held on October 29, 2025 to discuss the application for AMT-130, an investigational gene therapy for Huntingtons disease. In the final meeting minutes, the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 are currently unlikely to provide the primary evidence to support a BLA submission.
uniQure said it is evaluating the feedback and plans to urgently request a follow-up meeting with the FDA to take place in the first quarter of 2026.
Shares of uniQure are down 18% in pre-market trade on Thursday.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
